Data source
We conducted an independent review of citations from PubMed, EMBASE and
Cochrane library databases between January 1 1990 and October 31 2019.
Keywords were trastuzumab, lapatinib, pertuzumab, T-DM1, neratinib,
pyrotinib, anti-HER2 agents, HER2 blockade, breast cancer, breast
carcinoma, clinical trial and randomized. The search was limited to
prospective randomized clinical trials published in English. The search
strategy also used text terms such as anti-HER2 agents and HER-2
blockade to identify relevant information. We also performed independent
searches using EMBASE and Cochrane library databases between January 1
1990 and October 31 2019, to identify relevant trials. Additionally, we
searched abstracts containing the term “trastuzumab”, “lapatinib”,
“T-DM1”, “pertuzumab”,”anti-HER2 agents” that were presented at
the American Society of Clinical Oncology (ASCO) and the European
Society of Medical Oncology (ESMO) annual meetings from 2004 to 2013 to
identify relevant studies. Each trials was carefully reviewed and in
cases of duplicate publication only the most complete, recent and
updated report of the clinical trial was included for analysis.